Sang-hoon Ahn
Yonsei University · Medicine
About the Lab
Professor Sang-hoon Ahn's research lab focuses on chronic hepatitis B virus (HBV) infection, with a strong emphasis on understanding the virological, immunological, and genetic factors influencing disease progression. The lab investigates noninvasive biomarkers—such as SPRI, ASPRI, and APRI—for accurate staging of liver fibrosis and cirrhosis in treatment-naïve patients. It also explores the long-term impact of persistent HBV DNA replication on hepatocellular carcinoma recurrence and the role of host genetic factors, particularly HLA alleles, in determining infection outcomes. Additionally, the lab examines challenges in HBV management, including viral reactivation after stopping antiviral therapy due to persistent covalently closed circular DNA (cccDNA).
Research Overview
Research Output Trend
Figures are computed from collected data and may differ slightly.
Selected Papers
15TE can be performed with good diagnostic accuracy for quantifying liver fibrosis in patients with CHB.
Although chronic HBV infection is the leading cause of chronic liver disease and death worldwide, there are substantial differences in its clinical courses regarding prevalence, mode of transmission, characteristics of each phase, responses to antiviral therapy, and development of cirrhosis and hepatocellular carcinoma, according to geographical areas (Asia versus Western Europe and North America versus Africa). Furthermore, the clinical course in infected individuals depends on a complex interp
Although the mechanism of susceptibility to chronic persistent hepatitis B virus (HBV) infection is not well clarified, immunogenetic factors of the host may have a role. Recently, a strong association between HLA-DR13 and the self-limited course of HBV infection has been reported. To determine whether the elimination of HBV is related to a particular HLA allele, we studied the HBV markers and HLA-DR phenotypes of 1,272 Koreans who had visited Yonsei University Medical Center for renal transplan
BACKGROUND: Elevated serum hepatitis B virus (HBV) DNA increases the development of hepatocellular carcinoma (HCC). Rather than instantaneous DNA level, the duration of persistent HBV replication is more important in carcinogenesis. Nevertheless, most investigators evaluated the DNA level at study entry. We assessed the effects of persistently detectable serum HBV DNA on HCC recurrence. PATIENTS AND METHODS: We included 230 consecutive patients undergoing curative resection between 2000 and 2006
OBJECTIVES: Few noninvasive models of chronic hepatitis B (CHB) to predict liver cirrhosis have been studied. The aim of the current study is to investigate the diagnostic accuracy of two simple novel models of spleen-platelet ratio index (SPRI) and age-spleen-platelet ratio index (ASPRI) in patients with CHB. PATIENTS AND METHODS: A total of 346 consecutive treatment-naïve patients with CHB were retrospectively studied. The aspartate to alanine aminotransferase ratio (AAR), age-platelet index (
Chronic hepatitis B virus (HBV) infection is a major global health problem. It can cause progressive liver fibrosis leading to cirrhosis with end-stage liver disease, and a markedly increased risk of hepatocellular carcinoma. In the last two decades, substantial progress has been made in the treatment of chronic hepatitis, B. However, HBV is often reactivated after stopping nucloes(t)ide analogues because antivirals alone do not directly target covalently closed circular DNA, which is the templa
BACKGROUND: The accurate staging of hepatocellular carcinoma (HCC) is important in establishing treatment strategies and prognosis. Among tumor factors, microvascular invasion, one of TNM staging components and prognostic factors, is underestimated preoperatively, due to inaccuracy of imaging modalities. We investigated preoperative predictors of microvascular invasion. METHODS: We reviewed 190 consecutive HCC patients given curative resection from 1999 to 2006. All were treatment-naive and moni
Different cutoff LSM values according to ALT level and combination with age-spleen-platelet ratio index can enhance the performance of LSM in CHB, regardless of ALT level.
Current treatment guidelines suggest that antiviral therapy be considered for chronic hepatitis B (CHB) patients with high viral load if a biopsy shows significant liver disease despite alanine aminotransferase (ALT) levels two times or less than the upper limit of normal (ULN). We evaluated the histological findings in CHB patients with high viral load and persistently normal or slightly elevated serum ALT levels. Between January 2003 and June 2006, 105 consecutive treatment-naive patients with
The combination of LSM and API can avoid unnecessary invasive LB procedures in CHB patients.
LSPS is a reliable predictor for EVB risk. According to risk stratification, different prophylactic treatments should be considered for subgroups with LSPS≥6.5.
Research Areas
Dive deeper into Sang-hoon Ahn's research on Nubint
Open this lab's papers in the app to read with AI, summarize, and cite in your writing.